Targeting Evil Enhancers and Genes in AML

Intervenant(s)

Ruud Delwel

Événements

Colloque

09 Sep 2024

09:00 à 09:30

Hugues de Thé, Lise Alter & Matthieu Resche-Rigon

Deconstructing Niche Contributions to Disease Pathogenesis and Drug Resistance in AML

Unveil the Role of the Bone Marrow Vascular Niche in Acute Leukemia

Lessons from Azithromycin after allo-HSCT: how an antibiotic can promote relapse by disrupting immun…

Words from patients

AML Therapy in 2024: increasingly individualized approaches

VEXAS Syndrome in 2024

Colloque

09 Sep 2024

17:05 à 17:30

Régis Peffault de Latour

Paroxysmal Nocturnal Hemoglobinuria as an Original Non-Malignant Clonal Expansion Modulated by Compl…

Tracking Human Hematopoietic Stem Cell Clones in Health and Disease

Genomic and Clinical Heterogeneity within Adult Acute Lymphoblastic Leukemia

From Metabolic Vulnerabilities to Targeted Therapies in Leukemia

Developmental Origins of Childhood Leukemia: why does it matter?

AML: Lessons from the Genome

Targeting Evil Enhancers and Genes in AML

Targeting Cystine Import in AML

Mitochondrial Contributions to Hematopoietic Homeostasis and the Pathogenesis of Hematological Disor…

Targeting Microenvironmental Drivers of Blood Malignancies

Any Crosstalk in the Treatment of AML and HR-MDS

Clonal Evolution of Genetic Predisposition to Hematological Malignancies

PML Unravels New Insights into the Bases of AML Chemotherapy Response

Clonal Haemopoiesis: stem cell dynamics and stem cell response to inflammation

Voir aussi

Hugues de Thé, chaire Oncologie cellulaire et moléculaire

Premier symposium international THEMA Saint-Louis sur la leucémie

Targeting Evil Enhancers and Genes in AML

Session 7

Intervenant(s)

Ruud Delwel

Événements

Opening speech

Therapy Response and Resistance of AML Stem Cells to Venetoclax

Targetable Leukemia Dependency on Noncanonical PI3Ky Signaling

Overcoming Therapy Resistance in Acute Myeloid Leukemia

Regulation of Hematopoietic Stem Cell Dormancy

Unmasking Myeloproliferative Neoplasms Transformation Paths

AML State-Switched

Deconstructing Niche Contributions to Disease Pathogenesis and Drug Resistance in AML

Unveil the Role of the Bone Marrow Vascular Niche in Acute Leukemia

Lessons from Azithromycin after allo-HSCT: how an antibiotic can promote relapse by disrupting immun…

Words from patients

AML Therapy in 2024: increasingly individualized approaches

VEXAS Syndrome in 2024

Paroxysmal Nocturnal Hemoglobinuria as an Original Non-Malignant Clonal Expansion Modulated by Compl…

Tracking Human Hematopoietic Stem Cell Clones in Health and Disease

Genomic and Clinical Heterogeneity within Adult Acute Lymphoblastic Leukemia

From Metabolic Vulnerabilities to Targeted Therapies in Leukemia

Developmental Origins of Childhood Leukemia: why does it matter?

AML: Lessons from the Genome

Targeting Evil Enhancers and Genes in AML

Targeting Cystine Import in AML

Mitochondrial Contributions to Hematopoietic Homeostasis and the Pathogenesis of Hematological Disor…

Targeting Microenvironmental Drivers of Blood Malignancies

Any Crosstalk in the Treatment of AML and HR-MDS

Clonal Evolution of Genetic Predisposition to Hematological Malignancies

PML Unravels New Insights into the Bases of AML Chemotherapy Response

Clonal Haemopoiesis: stem cell dynamics and stem cell response to inflammation

Voir aussi